Updates are available Correction dated 2021-09-28
Click to view Correction: https://doi.org/10.1038/s41598-021-99041-1
-
Authors
Redhead, Martin A.
Owen, C. David
Brewitz, Lennart
Collette, Amelia H.
Lukacik, Petra
Strain-Damerell, Claire
Robinson, Sean W.
Collins, Patrick M.
Schäfer, Philipp
Swindells, Mark
Radoux, Chris J.
Hopkins, Iva Navratilova
Fearon, Daren
Douangamath, Alice
von Delft, Frank
Malla, Tika R.
Vangeel, Laura
Vercruysse, Thomas
Thibaut, Jan
Leyssen, Pieter
Nguyen, Tu-Trinh
Hull, Mitchell
Tumber, Anthony
Hallett, David J.
Schofield, Christopher J.
Stuart, David I.
Hopkins, Andrew L.
Walsh, Martin A.
-
Funding
Funding for this research was provided by:
Exscientia ltd
Diamond MX group
Hercules Foundation
Rega Foundation
Bill and Melinda Gates Foundation
- License Information
-
More Information
Article History
Received: 2 March 2021
Accepted: 10 June 2021
First Online: 24 June 2021
Change Date: 28 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-99041-1
Competing interests
: Exscientia Ltd. holds patents corresponding to the use of 1, 4, 5 and 8–13 for the treatment of coronavirus infection. The other authours have no competing interests to declare.
